First Patients Dosed in Trial of Radioactive Antibody for Prostate, Other Cancers

First Patients Dosed in Trial of Radioactive Antibody for Prostate, Other Cancers
The first three patients have been dosed in a clinical trial evaluating the safety and tolerability of MILGa, a radioactive antibody designed to seek out and destroy cancerous tumors in advanced prostate, bladder, and pancreatic cancer. The patients — two with pancreatic cancer and one with prostate cancer — have completed a one-month follow-up, and no

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *